CAN-FITE BIOPHA/S (CANF) Sees Significant Increase in Short Interest

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 356,891 shares, an increase of 11.7% from the October 15th total of 319,636 shares. Based on an average daily volume of 63,322 shares, the short-interest ratio is currently 5.6 days.

CAN-FITE BIOPHA/S stock traded down $0.01 during mid-day trading on Friday, reaching $1.33. The company had a trading volume of 41,500 shares, compared to its average volume of 151,759. CAN-FITE BIOPHA/S has a 52 week low of $1.12 and a 52 week high of $2.75.

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) last issued its quarterly earnings results on Friday, August 31st. The biotechnology company reported ($0.06) earnings per share for the quarter. The business had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $2.00 million.

Separately, HC Wainwright set a $8.00 price target on shares of CAN-FITE BIOPHA/S and gave the company a “buy” rating in a report on Wednesday, October 31st.

ILLEGAL ACTIVITY NOTICE: “CAN-FITE BIOPHA/S (CANF) Sees Significant Increase in Short Interest” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at


Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Recommended Story: How are institutional investors different from individual investors?

Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with's FREE daily email newsletter.

Leave a Reply